Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327948 · ClinicalTrials.gov registry record · NA
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt
A NA study, sponsored by Axonics.
- Completed
- Registry status
- NA
- Development phase
- 129
- Enrollment target
NCT03327948: Completed NA study, sponsored by Axonics.
NCT03327948 is a NA study that has completed, run by Axonics. The registered enrollment target is 129 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03327948, a NA study, has completed, sponsored by Axonics.
- COMPLETED
- Registry status
- NA
- Development phase
- 129 participants
- Enrollment target
Study Summary
The ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed or could not tolerate more conservative treatments.
Primary Outcome
Responders are defined as patients with greater than or equal to 50% reduction in symptoms
Interventions
- DEVICE Axonics Sacral Neuromodulation System (SNM) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2020-06-29 |
| Phase | NA |
What the finished NCT03327948 record still lists
NCT03327948 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Axonics Sacral Neuromodulation System (SNM) System is the first listed.
NCT03327948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03327948 about?
NCT03327948 is a clinical study titled "Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt". The ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed or could not tolerate more conservative treatments.
What is the current status of trial NCT03327948?
This trial is currently completed. It is a NA study. The enrollment target is 129 participants. The study started on 2017-11-21. Estimated completion is 2020-06-29.
What interventions are being tested in trial NCT03327948?
The interventions under investigation include: Axonics Sacral Neuromodulation System (SNM) System (DEVICE).
Who is sponsoring clinical trial NCT03327948?
This trial is sponsored by Axonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03327948's enrollment target sits among peer trials
129 744th of 2000 higher than 1,257 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI